SUBSCRIBE
SUBSCRIBE
News   Drug Development

GroPep Limited Changes Track From Psoriasis Drug To Asthma

December 14, 2005 | 
1 min read
Following poor efficacy in preclinical testing of its T-cell peptide drug candidate in psoriasis models, Adelaide biopharma GroPep (ASX:GRO) will undertake a market feasibility assessment for use of the drug in asthma.
Preclinical Australia
MORE ON THIS TOPIC
Biotechnology and molecular genetic engineering. 3D illustration of science and molecular technology.
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
January 26, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
January 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Pros and cons collage. Mixed media thumbs up and thumbs down hand gestures with speech bubbles. Review concept, positive and negative feedback vector illustration.
Immunology and inflammation
Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway
January 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Start early or business advantage. Businessman starts running ahead of competitors vector
Pain
Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill
January 22, 2026
 · 
2 min read
 · 
Tristan Manalac